GeneData (September 2002)
Genedata (USA), Inc. today announced the launch of version 4.0 of the GeneData Expressionist' Suite, GeneData?s acclaimed software system for life science professionals committed to large-scale microarray processing. The Expressionist Suite, comprised of three tightly integrated modules, is designed for the enterprise-wide analysis and management of gene expression data. The first of these modules, Expressionist Refiner, is a comprehensive data quality assessment tool with numerous normalization and correction functions. The relational database module, Expressionist CoBi, is a specially tuned Oracle® application for large-scale data storage and management. Expressionist Analyst, the third module, contains a comprehensive statistical package for the sophisticated analysis of complex data sets.
Version 4.0 of the GeneData Expressionist Suite features many new functionalities, including: Proprietary classification methods enabling prediction of toxic effects from novel chemical entities or the classification of biological samples, such as cancer tissues, based on gene expression profiles. Simultaneous multi-array processing capability, affording the most powerful error detection and correction of microarray data available, while facilitating high-throughput quality assessment and reporting. Innovative scripts to eliminate the tedium of repetitive tasks, providing timesaving automation in the streamlining and standardization of data analysis procedures.
Annotation for all Affymetrix GeneChip® layouts, including GenBank and Unigene accession numbers, LocusLink, MapLocation, Gene Symbol, as well as Gene Ontology biological processes, cellular components, and molecular functions. GeneData Company Profile GeneData is a leading bioinformatics company for in-silico functional genomics, offering high-quality software systems and solutions that accelerate life science research and the product development process. The company specializes in the integrated management and sophisticated analysis of experimental data generated by high-throughput technologies such as genome sequencing, gene expression profiling, protein expression profiling, metabolic profiling, and screening. Mapped to the life science research process, GeneData delivers various applications in areas such as toxicogenomics, pharmacogenomics, proteomics, metabolomics, post-genomics, diagnostics, chemical genomics, disease profiling, target identification, and validation.
Founded in 1997 as a spin-off from Novartis, the company is privately held and has grown to an interdisciplinary team of over 80 employees. GeneData is headquartered in Basel (Switzerland); has subsidiaries in Munich (Germany), San Francisco (U.S.A.), Boston (U.S.A.), and Oxford (U.K.); and is represented by Infocom Corporation in Tokyo (Japan). GeneData's partners include major pharmaceutical and biotechnology companies, life science organizations, and some of the world's most prestigious research institutions such as Altana Pharma, Arrow Therapeutics, AstraZeneca, Aventis, Bayer, diaDexus, the German Pathogenomics Network, Medigene, MWG-Biotech, NITE, Novartis, Pedigree Masterfoods, Philip Morris, Roche Pharma, Roche Vitamins, Schering, Stanford University, Syngenta, and the Universities of Wuerzburg, Goettingen and Minnesota. Disclaimer he statements in this press release that relate to future plans, events or performance are forward-looking statements that involve risks and uncertainties, including risks associated with uncertainties related to contract cancellations, manufacturing risks, competitive factors, uncertainties pertaining to customer orders, demand for products and services, development of markets for the Company's products and services. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. The Company undertakes no obligation to release publicly the result of any revisions to these forward-looking statements that may be made to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. This news article comes to you courtesy of www.bio.com